Please login to the form below

Not currently logged in
Email:
Password:

vedolizumab

This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Professor Carole Longson, director of NICE's health technology evaluation centre, said: Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when compared

Latest news

  • EC approves drugs for diabetes and Crohn’s disease EC approves drugs for diabetes and Crohn’s disease

    The European Commission ( EC) has approved Takeda's Entyvio ( vedolizumab) to treat adults with ulcerative colitis and Crohn's disease and Boehringer Ingelheim/Lilly's Jardiance ( empagliflozin), which adds to the growing list of treatments

  • FDA clears Takeda's <b>vedolizumab</b> for inflammatory bowel disease FDA clears Takeda's vedolizumab for inflammatory bowel disease

    FDA clears Takeda's vedolizumab for inflammatory bowel disease. Entyvio licensed for patients who have not responded to current therapies. ... The FDA approved Entyvio ( vedolizumab) to treat adults with moderate to severe ulcerative colitis ( UC) and

  • FDA panel backs Takeda's inflammatory bowel disease drug FDA panel backs Takeda's inflammatory bowel disease drug

    FDA panel backs Takeda's inflammatory bowel disease drug. Vedolizumab on course for US approval to treat Crohn's disease and ulcerative colitis. ... Takeda's Millennium Pharmaceuticals unit took a step closer to US approval for one of its top pipeline

  • FDA grants priority review to Takeda's colitis drug FDA grants priority review to Takeda's colitis drug

    FDA grants priority review to Takeda's colitis drug. Accelerates review time for vedolizumab. ... One of Takeda's top pipeline prospects - vedolizumab for ulcerative colitis ( UC) - has been given a priority review by the US Food and Drug Administration (

  • Phase III data raise hopes for Takeda's <b>vedolizumab</b> Phase III data raise hopes for Takeda's vedolizumab

    Phase III data raise hopes for Takeda's vedolizumab. Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease. ... Data from phase III trials of Takeda's inflammatory bowel disease ( IBD) drug vedolizumab suggests the company's

More from news
Approximately 7 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel ( TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel ( TAK-700),

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive

We are a healthcare, digital and innovation agency....

Latest intelligence

blog-icon_webinar_wow_c.png
E-detailing content wow factor in 2015
Many companies are reporting that the iPad novelty has worn off and healthcare professionals are demanding more than just another animation presented on a mobile device. So what exactly are...
Free White Paper: Multichannel Marketing for Pharma
Transitioning successfully to multichannel marketing takes careful planning. When done right, pharma can deliver a personalised experience for each customer. Download our white paper to learn how...
confirm_customer_understanding.png
How to confirm customer understanding in e-detailing
Done right, e-detailing takes away the guesswork in your marketing....